Imane Baghad1, Driss Erguibi2, Farid Chehab2, Sellama Nadifi3. 1. A PhD student of Centre of Doctoral study in health science-Doctoral training in genetics and molecular pathology -Laboratory of Genetics and Molecular Pathology, Medical School, University Hassan II, Casablanca BP 9154, Morocco. 2. General Surgery Department III, Ibn Rochd University Hospital Center, Casablanca BP 20102, Morocco. 3. Laboratory of Medical Genetics and Molecular Pathology, Faculty of Medicine and Pharmacy, Hassan II University, Casablanca, Morocco.
Abstract
BACKGROUND: Venous thrombosis has been described as a common complication for cancer patients. The association between clotting factor gene polymorphisms and the risk of colorectal cancer has been evidenced. The aim of the present study was to investigate the association of G20210A factor II prothrombin (FII) and factor V Leiden ( FVL) G1691A with the risk of colorectal cancer(CRC). METHODS AND RESULTS: Genotyping of FVL and G20210A FII was performed using the polymerase chain reaction restriction fragment length polymorphism method on a sample of 76 patients with CRC as well as 182 controls. No significant difference in FVL gene variations was observed between cases and controls. However, with regard to the G20210A FII, the homozygous mutated genotype AA was associated with an increased risk of CRC. A significant association between the G20210A FII mutation and the risk of CRC was identified using recessive (OR=57.63, 95% CI: 3.33-997.26, P=0.0053), dominant (OR=27.87, 95% CI: 12.67 -61.28, P<0, 0001) and additive (OR=21.24, 95% CI: 10.45-43.16, P<0, 0001) models. No statistical difference was observed in parameters such as sex, age and positive family history for cancer. CONCLUSION: Our results did not support an effect of FVL gene on CRC risk and suggested that the G20210A FII prothrombin gene variant may be a risk factor for CRC in Moroccan population.
BACKGROUND: Venous thrombosis has been described as a common complication for cancer patients. The association between clotting factor gene polymorphisms and the risk of colorectal cancer has been evidenced. The aim of the present study was to investigate the association of G20210A factor II prothrombin (FII) and factor V Leiden ( FVL) G1691A with the risk of colorectal cancer(CRC). METHODS AND RESULTS: Genotyping of FVL and G20210A FII was performed using the polymerase chain reaction restriction fragment length polymorphism method on a sample of 76 patients with CRC as well as 182 controls. No significant difference in FVL gene variations was observed between cases and controls. However, with regard to the G20210A FII, the homozygous mutated genotype AA was associated with an increased risk of CRC. A significant association between the G20210A FII mutation and the risk of CRC was identified using recessive (OR=57.63, 95% CI: 3.33-997.26, P=0.0053), dominant (OR=27.87, 95% CI: 12.67 -61.28, P<0, 0001) and additive (OR=21.24, 95% CI: 10.45-43.16, P<0, 0001) models. No statistical difference was observed in parameters such as sex, age and positive family history for cancer. CONCLUSION: Our results did not support an effect of FVL gene on CRC risk and suggested that the G20210A FII prothrombin gene variant may be a risk factor for CRC in Moroccan population.
Entities:
Keywords:
Colorectal cancer; G20210A Factor II prothrombin; Moroccan population; factor V Leiden; sporadic
Authors: Gyula Mózsik; György Rumi; András Dömötör; Mária Figler; Beáta Gasztonyi; Elod Papp; Alajos Pár; Gabriella Pár; József Belágyi; Zoltán Matus; Béla Melegh Journal: World J Gastroenterol Date: 2005-12-28 Impact factor: 5.742
Authors: R M Bertina; B P Koeleman; T Koster; F R Rosendaal; R J Dirven; H de Ronde; P A van der Velden; P H Reitsma Journal: Nature Date: 1994-05-05 Impact factor: 49.962